摘要
目的观察重组干扰素α－２ａ，α－２ｂ抗丙型肝炎病毒（ＨＣＶ）的近、远期疗效。方法重组干扰素α－２ａ治疗组７０例，重组干扰素α－２ｂ４６例对照组２８例，治疗后随访５年。结果治疗结束时，ＨＣＶＲＮＡ阴转率和血清ＡＬＴ复常率α－２ａ组分别为６７１４％和７０００％，α－２ｂ组分别为６９５６％和７１７３％，随访５年后，α－２ａ组ＨＣＶＲＮＡ阴转率和血清ＡＬＴ复常率分别为３５７１％和４７１４％，α－２ｂ组分别为３９１３％和５２１７％，均显著高于对照组（Ｐ＜００１和Ｐ＜００５）。基因分型以ＨＣＶⅠ组感染为主（７５８６％），干扰素对ＨＣＶⅡ组感染的疗效优于ＨＣＶⅠ组。结论重组干扰素α－２ａ与α－２ｂ均为有效的抗丙型肝炎病毒药物，慢性丙型肝炎患者干扰素治疗的早期疗效较好。
In order to discuss the anti-viral effects of IFNα-2a and IFNα-2b on chronic hepatitis C in a short and long period of time after treatment, 70cases of chronic hepatitis C treated with IFNα-2a, 46 cases with IFNα-2b and 28 cases as controls had been investigated in this study. The follow-up time began from half to 5 years. The serum negative conversion rate of HCV RNA and the normalization of serum alanine transaminsae(ALT)were detected at the end of treatment and up to 5 years after therayp. The negative seroconversion rate of HCV RNA and the serum ALT normairlization were 67.14% and 70.00% respectively in IFNα-2a group and 69.56%, 71.71% respectively in IFNα-2b group at the end of the treatment. After 5-year follow-up, the above two lndexs were 35.71%, 47.14%respectively in IFNα-2a group, and 39.13%,52.17%respectively in IFNα-2b group. The effectiveness in treated patients was higher than that of controls (P<0 01 and P<0.05). Recombinant IFNα-2a and IFNα-2b are effective medicines for HCV infection. And interferon therapy had a high short-term complete response but a low long-term complete response in the treatment of chronic hepatitis C.HCV genotype seems to be an important factor in determining the response rate to IFN treatment in patients with chronic hepatitis C.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
1998年第4期373-376,共4页
Chinese Journal of Experimental and Clinical Virology
